ABSTRACT Glucagon-like peptide-1 (GLP-1) release in response to food ingestion has been associated with decreased food intake. In the present study, we tested the hypothesis that the feeding response to GLP-1 injection into the hypothalamic paraventricular nucleus (PVN) is influenced by the macronutrient composition of the food consumed. In the first experiment, rats were injected with GLP-1 (0.2 g) or saline (0.5 L) in the PVN at dark onset (1800 h), and food intake from a maintenance diet (18% protein) was measured at 1, 2 and 14 h. In Experiment 2, after GLP-1 injection, rats were fed a carbohydrate (protein-free) diet for the first 2 h or gavaged with glucose (1.4 g/5 mL). In Experiment 3, after GLP-1 injection, rats were fed a protein (50%) diet for the first 2 h, or were preloaded with egg albumin (1.0 g). In the last experiment, GLP-1 was given after corn oil gavage (2.4 g). GLP-1 injection resulted in a reduced consumption of the maintenance diet from 2 to 14 h. The decreased food intake from 2 to 14 h after GLP-1 administration occurred after carbohydrate intake, either by meal or preloads, but not after protein intake, either as a meal or preload. A transient interaction of GLP-1 with a corn oil gavage was detected but only in early feeding (0 -2 h). We conclude that the effect of GLP-1 injected in the PVN on food intake is influenced by the macronutrient composition of the food consumed. Carbohydrate enhances, protein blocks and corn oil has a transient effect on the suppression of food intake caused by GLP-1 in the PVN. J. Peptides known to function in the regulation of food intake have been found in both the gastrointestinal tract and brain (1), and some of them have been shown to interact only with specific nutrients (2). For example, the reduced food intake occurring after preloads of protein (egg albumin) was completely blocked by pretreatment with the cholecystokinin-A (CCK-A) 4 receptor antagonist (3,4). Because the CCK-A receptor antagonist did not block the food intake suppression caused by preloads of cornstarch, corn oil or an amino acid mixture patterned after albumin, it was concluded that there is a specific interaction between the CCK receptor and the protein to induce satiety in rats (3,4).
Peptides known to function in the regulation of food intake have been found in both the gastrointestinal tract and brain (1) , and some of them have been shown to interact only with specific nutrients (2) . For example, the reduced food intake occurring after preloads of protein (egg albumin) was completely blocked by pretreatment with the cholecystokinin-A (CCK-A) 4 receptor antagonist (3, 4) . Because the CCK-A receptor antagonist did not block the food intake suppression caused by preloads of cornstarch, corn oil or an amino acid mixture patterned after albumin, it was concluded that there is a specific interaction between the CCK receptor and the protein to induce satiety in rats (3, 4) .
Glucagon-like peptide-1 amide (GLP-1) is a braingut peptide that suppresses food intake both when intravenously infused in humans (5) (6) (7) (8) and when administered centrally (via lateral or 3rd ventricle) (9 -16) and peripherally in rats (17). Its action is blocked by prior treatment with its specific receptor antagonist, exendin 9 -39, in rats (10 -14,16,18) .
The primary metabolic role of GLP-1 appears to be to regulate carbohydrate metabolism through its effects on glucose-dependent insulin release, inhibition of glucagon secretion and stimulation of glycogenesis in the liver and muscle (19 -23) . Carbohydrate, fat and protein meals cause the release of GLP-1 in humans (24 -27) . GLP-1 has also been shown to be released in rats after ingestion or infusion into intestinal segments of mixed meals (28) , carbohydrate (29, 30) , fat (31, 32) and peptones (33) .
In rats, carbohydrate appears to be the primary stimulant of GLP-1 secretion (34) . Most carbohydrates including glucose, galactose and fructose, stimulate GLP-1 secretion in rats (29, 30, 34, 35) . Only some fats and bile acids show stimulatory effects on GLP-1 release (29, 34) .
Interactions between macronutrient composition and GLP-1 release in determining the feeding response of rats have not been reported. Therefore, the objective of this study was to test the hypothesis that GLP-1 injected into the paraventricular nucleus of the hypothalamus (PVN) exerts a greater interaction with carbohydrate than with protein or fat intake on the regulation of subsequent food intake in rats.
MATERIALS AND METHODS

Animals and diets.
Male Wistar rats (Charles River Laboratories, St. Constant, Quebec, Canada) were individually housed in hanging wire-mesh stainless steel cages in a room maintained at 22 Ϯ 1°C and a 12-h:12-h light:dark cycle (lights on at 0600 h). Upon arrival, rats were allowed free access to nonpurified diet (LabChow #5001; Agribrands, Ontario, Canada) for 24 h/d until fed the experimental diets and to water from spouts of an automated watering system throughout the experiment. For measuring the weights of food cups and spillage, a 40-W red light was on between 1730 and 2100 h.
In some experiments, rats were fed an AIN-93G diet (17.7% protein) (36) between 1800 and 0800 h; in other experiments, the diet was replaced with either a protein-free, high carbohydrate (CHO) diet or a high protein, low carbohydrate (PRO) diet for the first 2 h (1800 -2000 h). The composition of the maintenance (AIN-93G) diet is shown in Table 1 . The CHO (88.3% carbohydrate) diet and the PRO (50% protein) diet were isocalorically formulated by adding or removing casein and L-cystine at the cost of the cornstarch in the AIN-93G diet (Table 1 ). This study was approved by the University of Toronto Animal Care Committee.
Reagents. GLP-1 (Peninsula Laboratories, San Carlos, CA) was dissolved as 80% peptide content with Ͼ97% purity. Because a vial of 0.2 mg GLP-1 contained 160 g of the peptide, 800 L of filtrated, deionized water was added to the vial. After the powder was completely dissolved by gentle shaking by hand for 5 min, 40-L aliquots were frozen on dry ice and vacuum freeze-dried at Ϫ70°C for 1 h (Savant Speed Vac SC100 and Vertis Freezemoble 12). The dry powder was stored at Ϫ20°C for a maximum of 6 mo until utilization.
Within 2 h before injections on experimental days, a vial containing 8 g of GLP-1 was freshly dissolved in 20 L of 9 g/L NaCl solution over 5 min by gently blowing air into the solution using its injection cannula attached to a 1-mL syringe via Tygon tubing (see below). The solution was then taken up for injection.
Both deionized water and saline were filtered through a 0.2-m micropore filter (Gelmann Sciences, Montreal, Canada) to remove pathogens. The injectors and tubing were thoroughly washed with 70% ethanol and dried for a day before use. The stylets were wiped with 70% isopropyl alcohol swabs (Ingram & Bell Medical, Don Mills, Canada).
Anhydrous D-glucose (1.4 g/rat) was obtained from BioBasic (Toronto, Canada), chicken egg albumin (1.0 g/rat) from Sigma (St. Louis, MO) and corn oil (Mazola) (2.4 g/rat) from a local supplier. They were either dissolved or suspended by using a magnetic stirrer in deionized water (5 mL) and intragastrically provided to rats using a 16-gauge feeding needle (4) . The amounts of preloads were based on evidence that when preloaded by gavage, they suppress food intake in rats for the first 2 h by ϳ30 -40% compared with control (Peters et al, unpublished data) (4) . The amount of GLP-1 (0.2 g/rat) to be injected was chosen because it decreases food intake in rats when injected into the PVN (37, 38) .
Surgery. Rats (300 g) under anesthesia with sodium pentobarbital (Somnotol, MTC Pharmaceuticals, Cambridge, Canada; 40 mg/kg intraperitoneally) were aseptically implanted with a single 22-gauge stainless steel guide cannula (Plastics One, Roanoke, VA) 2 mm dorsal to the right side of the PVN, with coordinates of 1.8 mm posterior to the bregma, 0.5 mm lateral to the midline and 6.0 mm ventral to the surface of the skull (39) using a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA). The guide cannula was secured to the surface of the skull with four stainless steel screws and dental cement, and then a 28-gauge obturator inserted into the guide cannula to prevent tissue entry. An antibiotic (Penlong XL, 0.03 mL; Pfizer Canada, London, Canada) was administered intramuscularly to one thigh of the rats after the surgery. An analgesic (Temgesic, 0.05 mg/kg; Reckett & Colman Pharmaceuticals, Hull, UK) was provided subcutaneously to relieve the postoperative pain. For postoperative recovery, rats were given 1 wk, during which they were closely monitored but no treatments were given. Allowing rats to have free access to the diet during this period appeared to contribute to a rapid recovery from the surgery.
Procedures. To accustom the rats to gavage procedures, from the day after their delivery, each rat received 5 mL of deionized water by gavage. After 1-wk recovery from surgery, handling of rats was resumed each day 2 h before the dark onset. This included weighing, three mock injections and water preloads by insertion of a 16-gauge, 75-mm length, 3-mm ball diameter feeding needle (Fine Science Tools, North Vancouver, Canada) attached to a 5-mL syringe. Beginning a week before behavioral tests, the AIN 93G diet was provided to rats in some experiments from 1800 to 0800 h instead of nonpurified diet; in other experiments, either the CHO diet or the PRO diet was fed for the first 2 h (1800 -2000 h) and then the maintenance diet for the rest of the night.
Before injections, each rat was transferred from its own cage to a cardboard box with dimensions of 25 cm ϫ 25 cm ϫ 25 cm; daily body weight and injections were performed in the boxes while rats were allowed to move freely. Injection of substances (in a volume of 0.5 L) was performed over 50 s using an injection cannula (28-gauge) (Plastics One). The cannula was connected to a Hamilton microsyringe (5.0 L, #87920) via Tygon Tubing (i.d., 0.19 cm; o.d., 0.20 cm; Cole-Parmer Instrument Company, Vernon Hills, IL). The injection cannula was left in place for an additional 1 min to allow the substances to diffuse into tissues before removal; rats were then returned to their own cages after placement of the obturator. The cannula extended 2 mm ventrally from the tip of the guide to reach the PVN. To minimize drug-carryover effects, each injection day was followed by a 2-d washout period during which no injections were given. Each rat served as its own control. Food was provided in a white china cup, 40 mm in height, and 60 and 70 mm in i.d. and o.d., respectively. Food consumption was measured at 1, 2 and 14 h after food introduction (1800 h) to the nearest 0.1 g with adjustment for spillage.
Design. Four experiments were designed in which each rat served as its own control. One group (n ϭ 8) was prepared for Experiment 1, and another group (n ϭ 12) for Experiments 2-4. Both treatment order and group assignment were randomized for each experiment. At 1800 h (meal studies: Experiments 1, 2A and 3A) or 1730 h (preload studies: Experiments 2B, 3B and 4) on experimental days, rats were divided into two groups. One group was injected with GLP-1 (0.2 g/0.5 L) into the PVN and the other saline (0.5 L) at 1800 h (meal studies); in preload studies, injections were made, followed by nutrient preloads given by gavage at 1730 h. Food cups were introduced at 1800 h, and food intake and spillage measured at 1, 2 and 14 h thereafter. After a 2-d washout period, the order of these treatments was reversed, i.e., rats that received GLP-1 on d 1 were given saline and rats that received saline were injected with GLP-1.
Experiment 1. Effect of GLP-1 injection into the PVN on intake of the AIN-93G diet.
To test the effect of GLP-1 injection into the PVN on consumption of the maintenance diet, the AIN-93G diet was provided for 14 h after injections of GLP-1 or saline. 
Experiment 2. Effect of GLP-1 injection into the PVN in com-
bination with either the CHO diet or glucose preloads on subsequent food intake. In Experiment 2A, the CHO diet was provided from 1800 to 2000 h after injections and the AIN-93G diet from 2000 to 0800h. In Experiment 1B, immediately after both GLP-1 and saline injections (1730 h), all rats were gavaged with glucose (1.4 g/5 mL) and 30 min later fed the AIN-93G diet for 14 h. Experiment 3. Effect of GLP-1 injection in combination with either the PRO diet or egg albumin preloads on subsequent food intake. The design of these experiments was identical to that in Experiment 2, except that the PRO diet was fed in Experiment 3A and egg albumin (1.0 g) gavaged in Experiment 3B.
Experiment 4. Effect of GLP-1 injection into the PVN and corn oil preloads on food intake. The design of this experiment was similar to that of Experiments 2B and 3B, except that corn oil (2.4 g/5 mL) was given to all rats by gavage at 1730 h.
Histology. At the conclusion of the experiments, the rats were injected with 2% Evans Blue dye (Sigma) in 9 g/L NaCl into the PVN in the same procedures as peptide injection, and killed by CO 2 gas. Their brains were removed and soaked for several days in 10% formaldehyde solution in 9 g/L saline and for 2 d in 300 g/L sucrose solution. After fixation, 40-m frozen sections of the brain were cut, mounted on glass slides and subsequently dehydrated and stained with Cresyl violet (Aldrich, Milwaukee, WI). To verify the accuracy of the cannula placements, the sections were examined by light microscopy with reference to the atlas of the brain of Paxinos and Watson (39) .
Statistical analysis. Data analysis was performed by a paired t test using the SAS System (SAS Institute, Cary, NC). Data were expressed as means Ϯ SEM. All treatment effects were considered significant at P Յ 0.05.
RESULTS
The data for rats in which the location of cannula was Ͼ 0.5 mm from the PVN (40) were excluded from the analysis. A typical placement of cannula in the PVN is shown in Figure  1 . The numbers of rats with cannula placed in the PVN were 6 for Experiments 1 and 10 (2, outside the PVN) for Experiments 2A-4.
Rats injected with GLP-1 significantly reduced consumption of the maintenance diet. Although the full 0 -14 h consumption was reduced, it occurred from 2 to 14 h, but not earlier. Food intake was 15.7 g for 2-14 h after GLP-1 compared with the saline control (19.7 g) (t ϭ 2.99, P Ͻ 0.03) and 22.8 g for 0 -14 h vs. 26.9 g (t ϭ 2.21, P Ͻ 0.054), respectively (Table 2, Expt. 1).
When GLP-1 was provided concurrently with carbohydrate, whether given by meal ( GLP-1 injection had no effect on food intake when given with the PRO diet or albumin preloads. No difference in food intake occurred over 14 h between the saline and GLP-1 treatments (Table 2 , Expts. 3A and 3B) (P Ͼ 0.05). When the PRO diet was fed for the first 2 h, food consumption from 2 to 14 h was 14.6 g after saline vs. 13.5 g after GLP-1 (P Ͻ 0.45), and the total 14 h intake was 22.0 g vs. 20.6 g (P Ͻ 0.41), respectively (Table 2, Expt. 3A). Similar results were seen after albumin preloads, with food intake from 2 to 14 h of 14.9 g for saline vs. 13.7 g for GLP-1 (P Ͻ 0.49) and 20.1 g vs. 19.8 g (P Ͻ 0.84) for the total 14 h intake (Table 2, Expt. 3B).
When GLP-1 was combined with corn oil, a slight but significant reduction was detected only for the cumulative 0 -2 h food intake (Table 2, Expt. 4). Food consumption was as follows: 0 -1 h, 2.3 g (saline) vs. 1.9 g (GLP-1) (t ϭ 2.18, P Ͻ 0.072); 0 -2 h, 3.9 g vs. 3.3 g (t ϭ 3.08, P Ͻ 0.03).
DISCUSSION
The aim of the present study was to test the hypothesis that the feeding response to GLP-1 in the PVN is influenced by the macronutrient content of the food ingested. The results show that when given alone or concurrently with carbohydrate as a meal or preloads, GLP-1 injection into the PVN decreased food intake over 2-14 h. In contrast, protein intake prevented the reduction in food intake caused by GLP-1. When combined with corn oil, GLP-1 decreased food intake only from 0 to 2 h. Thus, the present results suggest that interactions occur between GLP-1 in the PVN and the composition of the macronutrient ingested.
The decreased intake of the maintenance diet after GLP-1 is in general agreement with previous reports. However, the time course of the response is not. Intracerebroventricular injection of GLP-1 suppresses feeding behavior in both fooddeprived and freely fed rats (9 -16,18,41), a result that is abolished by pretreatment with its receptor antagonist, exendin 9 -39 (16) . Suppression of food intake from a nonpurified diet has been found to be rapid, within 2 h of GLP-1 injections (9 -16,18,41). McMahon and Wellman (37,38) recently reported a reduction in food intake of a palatable liquid meal or pelleted nonpurified diet within 1 h after GLP-1 (0.2 g) injection into the PVN of fed rats.
The primary effect of GLP-1 on food intake in the present study occurred from 2 to 14 h (Table 2, Expt. 1). It is unlikely that our observation resulted from a delayed diffusion rate of the GLP-1 injected in the PVN to bind to its receptors because GLP-1 injection combined with the corn oil preload resulted in a reduction in food intake over 0 -2 h (Table 2, Expt. 4). An explanation likely resides in the feeding method. McMahon and Wellman (37, 38) injected GLP-1 (0.2 g/rat) into the PVN of freely fed rats in experiments that were performed during the day, starting 4 or 2 h before dark onset, respectively. In the present study, however, the rats were deprived of food daily for 10 h, and food was available only from 1800 h (dark onset) to 0800 h the next morning. GLP-1 (0.2 g/rat) was injected either 30 min before or at the dark onset, depending on the experiment. Because of food deprivation during the day and the normal surge in feeding activity of rats as they enter the night time feeding period, rats in this study started to eat immediately after the peptide was injected and food provided.
The present results suggest that the action of GLP-1 on feeding behavior is enhanced by signal(s) arising after carbohydrate, but not protein consumption (Fig. 2) (Table 2 , Expts. 2A-3B). Carbohydrate ingestion increases release of GLP-1, a potent insulin secretagogue, inhibits glucagon secretion, and stimulates glycogenesis in the liver and muscle and lipogenesis in adipose tissue (21) . Because insulin release enhances glucose uptake by tissues and increased metabolism of glucose has been associated with food intake control mechanisms, it is reasonable to expect that the action of GLP-1 would be enhanced by CHO intake. GLP-1 alone resulted in a 20% reduction in consumption of the AIN diet for 2-14 h but led to a 36% decrease when the CHO diet was fed. This enhancement was not seen after other treatments (glucose, 17%; albumin, 8%, PRO, 9% decrease; but corn oil, 19% increase) (Fig. 2) .
There may be several pathways by which signals derived from carbohydrate consumption interact with the GLP-1 injected in the PVN to suppress food consumption. First, the availability of carbohydrate (glucose) is monitored by glucosesensing mechanisms existing in both the pancreatic ␤-cells and the brain. Several hypothalamic areas have been found to coexpress glucokinase and glucose transporter 2 with GLP-1 receptors (12, 42, 43) . Thus it is likely that glucose directly activates these mechanisms, resulting in the enhancement of the negative effect of GLP-1 injected into the PVN on food intake. Second, GLP-1 signaling appears to depend on both the afferent and efferent fibers of the vagus through which the information is transmitted and integrated into the nucleus tractus solitarius (NTS) and then other brain sites such as the PVN. The PVN and the arcuate nucleus (ARC) express GLP-1 receptor mRNA and are intensively innervated by GLP-1 immunoreacitve nerve fibers from GLP-1 perikarya in the NTS (44 -47) . For example, the delayed gastric emptying elicited by GLP-1 is lost after either vagal denervation with capsaicin in rats (6) or vagotomy in humans (48) and pigs 1 Mean Ϯ SEM, n ϭ 6, 8, 10, 6, and 7 for Experiments 1, 2A and 2B, 3A, 3B and 4, respectively. Rats served as their own control. Food was provided only from 1800 to 0800 h, but water was available for 24 h daily. 2 Immediately after GLP-1 or saline injection at 1800 h, the AIN-93G diet was provided for 0 -14 h, or either a protein-free, high carbohydrate (CHO) diet or a high protein, low carbohydrate (PRO) diet for the first 2 h and the AIN-93G diet for the rest of the night (2-14 h). 3 Immediately after GLP-1 or saline injection at 1730 h, glucose (1.4 g/5 mL), chicken egg albumin (1.0 g/5 mL) or corn oil (2.4 g/5 mL) was preloaded by gavage and 30 min later, the AIN-93G diet provided for 0 -14 h. * , ** Different from saline at P Ͻ 0.05 and P Ͻ 0.01, respectively, by a paired t test.
(49). Thus, the suppressive effect of GLP-1 on gastric motility may account in part for GLP-1-induced satiety. Third, the circulating GLP-1 is able to enter the brain by crossing the blood-brain barrier (BBB) (50) and binds to its receptors in several brain regions in which the BBB is relatively leaky. Among those are the subfornical organ, area postrema, median eminence and pituitary (23,51,52), which have a high density of GLP-1 receptors (51) as well as close neuroanatomical connections with hypothalamic areas such as the PVN and ARC (53) . Fourth, GLP-1 has been shown to interact with a variety of neurotransmitters in the brain, such as neuropeptide Y (NPY) (13,16), corticotrophin-releasing hormone (CRH) (54) and leptin (10, 53) . Because both NPY and CRH are associated with carbohydrate intake (55, 56) , for example, GLP-1 may suppress food intake by suppressing the elevation of NPY found after food intake and increasing corticosterone in plasma via activation of the CRH neurons in the PVN (54, 56) . Injection of CRH into the PVN, but not elsewhere in the hypothalamus, reduces NPY-induced feeding (57) . Food intake was suppressed by 17% during the 2-14 h period compared with saline when GLP-1 was combined with glucose gavage, whereas an ϳ36% reduction in food intake was observed after treatments of GLP-1 and the CHO diet. The weaker feeding response after GLP-1 with glucose preloads, compared with the CHO diet, may be accounted for by the smaller size, the bolus nature of the glucose preloads and perhaps the 30-min delay between these treatments and presentation of the AIN-93G diet. Evidence has shown that GLP-1, and thereby insulin, is rapidly released in response to intragastric loads of glucose in rats and reaches a peak within 5 (58) or 30 min (59) . Because glucose preloads were given 30 min before feeding in the present study, a peak of GLP-1 release caused by glucose preloads may have passed, whereas consumption of the CHO diet would have continued to stimulate GLP-1 release over the 2-h feeding interval, resulting in a stronger suppression of subsequent food intake.
Protein intake prevented the decrease in food consumption caused by GLP-1, implying that protein consumption interrupts the pathways by which GLP-1 reduces food intake. It has been speculated that protein is a weak stimulant of GLP-1 release in rats, as it is in humans (24, 25) , with little interaction occurring between peripheral and central actions of GLP-1, although the effect of protein ingestion on GLP-1 release and the time course in rats has not been reported (34) . It seems likely that signals arising from GLP-1 release may have been surpassed by others derived from protein consumption, which itself strongly suppresses food intake through other mechanisms (unpublished data) 5 (3, 4) . For example, CCK is strongly released in response to the presence of protein in the upper small intestine (60) and both central and peripheral injections of CCK robustly suppress food intake (61) . We recently showed that CCK-A receptors are involved in the reduced food intake occurring after preloads of protein (egg albumin) (3, 4) .
The results showing that corn oil preloads in conjunction with GLP-1 slightly, but significantly decreased food intake only during early feeding are consistent with the time course of GLP-1 release after corn oil consumption. Fat, including corn oil, enhances GLP-1 release after ingestion (32, (62) (63) (64) . GLP-1 secretion peaks within 5 min and lasts for ϳ1 h after the infusion of corn oil (3-4 mL) into the proximal segment of rat duodenum (32) . In pigs, a peak of GLP-1 release was observed at 60 min after fat infusion (soybean oil) into the duodenum, followed by a gradual decrease without significant difference from baseline at 90 min (63) . Thus, peak action of GLP-1 after corn oil gavage would be expected in the first 2 h of food access.
To confirm that the GLP-1 was biologically active over the duration of these studies, we measured the effect of the peptide GLP-1 (lot #: 802902) on heart rate (beats/min) in male Wistar rats (65, 66) at the end of the series of experiments. Rats (470 g) were anesthetized as described previously (67) . After 20 min, heart rate (beats/min) was measured every 3 min for 1 h using Pulse Oximeters (Nonin 8600V, Nonin Medical, FIGURE 2 Change in food intake after glucagon-like peptide-1 (7-36) amide (GLP-1) (0.2 g/0.5 L) injection into the paraventricular nucleus of the rat hypothalamus. At each measurement interval, the percentage of change in food intake was calculated as follows: change (%) ϭ 100 ϫ [intake (g) after GLP-1 injection Ϫ intake (g) after saline injection]/intake (g) after saline injection. For example, mean change (%) in food intake for 0 -1 h in Table 2 4 g ), given by gavage, were provided to all rats. At 1800 h, the AIN diet was provided for 14 h. *P Ͻ 0.05; **P Ͻ 0.01.
Minneapolis, MN)
. Approximately 20 min after a constant baseline was observed, GLP-1 (2 g/0.5 mL saline) or saline (0.5 mL) was injected intravenously via the tail vein over 2 min (2 rats each group). GLP-1 injection increased heart rate in both rats (8% at 12 min and 16% at 6 min after the injection), whereas saline injection did not. Therefore, the failure to see a feeding response to the GLP-1 when given with protein preloads or the PRO diet cannot be explained by the absence of biological activity of the preparation. Furthermore, GLP-1 activity was also found in the final experiment in which it enhanced food intake suppression by a corn oil preload ( Table 2 , Expt. 4).
Central injection of GLP-1 has been shown to cause conditioned taste aversion (CTA). When intracerebroventicular GLP-1 at 1.0 or 3.0 g was followed by immediate oral infusion of saccharin, rats reexposed to GLP-1 and saccharin after several days rejected the saccharin after the 3.0 g dose (41). It is unlikely that the reduced food intake in the present study resulted from CTA by GLP-1. For example, McMahon and Wellman (38) showed previously that a 0.2 g GLP-1 injection (the same amount used in the present study) into the PVN did not cause CTA in rats. Moreover, we did not observe any consistent pattern of eating over a series of experiments that might be interpreted as a CTA response. Because no suppression in food intake was seen in rats treated with GLP-1 and protein, it is unlikely that the decreased food intake after GLP-1 injection resulted from CTA.
Studies conducted to date on the effect of GLP-1 provided centrally to experimental animals have tested total food intake from a single diet. Because GLP-1 exerts a critical effect on carbohydrate metabolism and its effect on subsequent food intake is enhanced by carbohydrate intake, it may be that central GLP-1 also plays a role in regulating macronutrient selection and intake. Evidence for this possibility is supported indirectly by recent studies of the effect of peripheral injections of a GLP-1 agonist and an antagonist. When rats were given a choice between CHO and PRO diets, and received intraperitoneal injections of the GLP-1 receptor antagonist, exendin 9 -39, a selective decrease was observed in intake of only the CHO diet, whereas a GLP-1 receptor agonist, exendin 4, caused a selective decrease in intake of only the PRO diet (Peters et al, unpublished data).
We concluded that the effect of GLP-1 injected into the PVN on food intake is influenced by the macronutrient composition of the food consumed. Carbohydrate enhances, protein blocks and corn oil has a transient effect on the suppression of food intake caused by GLP-1 in the PVN.
